Thermaquil is developing reversible, drug-free nerve-block devices for pain and conditions associated with overactive nerve signaling. Its thermal approach briefly warms a nerve and then cools it to sustain a block. University of Pittsburgh researcher Changfeng Tai and founding CEO Stephen Popielarski formed the company in 2017. [1]
The company’s research includes a wearable device targeting occipital nerves for severe head and neck pain, supported by a $1 million NSF SBIR Phase II award. Thermaquil also served as commercialization partner on a DARPA-funded collaboration with Tai’s laboratory investigating ways to restore bladder function after complete spinal cord injury. [2] [3]